121 related articles for article (PubMed ID: 38364204)
1. Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis.
Ikeda S; Ogura T; Kato T; Kenmotsu H; Agemi Y; Tokito T; Ito K; Isomoto K; Takiguchi Y; Yoneshima Y; Yokoyama T; Harada T; Tanzawa S; Kobayashi N; Iwasawa T; Misumi T; Okamoto H
Ann Am Thorac Soc; 2024 Apr; 21(4):635-643. PubMed ID: 38364204
[No Abstract] [Full Text] [Related]
2. Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis.
Ikeda S; Ogura T; Kato T; Kenmotsu H; Iwasawa T; Misumi T; Yamanaka T; Okamoto H
Ther Adv Med Oncol; 2020; 12():1758835920923431. PubMed ID: 32489433
[TBL] [Abstract][Full Text] [Related]
3. Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis.
Otsubo K; Kishimoto J; Kenmotsu H; Minegishi Y; Ichihara E; Shiraki A; Kato T; Atagi S; Horinouchi H; Ando M; Kondoh Y; Kusumoto M; Ichikado K; Yamamoto N; Nakanishi Y; Okamoto I
Clin Lung Cancer; 2018 Jan; 19(1):e5-e9. PubMed ID: 28687482
[TBL] [Abstract][Full Text] [Related]
4. Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.
Otsubo K; Kishimoto J; Ando M; Kenmotsu H; Minegishi Y; Horinouchi H; Kato T; Ichihara E; Kondo M; Atagi S; Tamiya M; Ikeda S; Harada T; Takemoto S; Hayashi H; Nakatomi K; Kimura Y; Kondoh Y; Kusumoto M; Ichikado K; Yamamoto N; Nakagawa K; Nakanishi Y; Okamoto I
Eur Respir J; 2022 Dec; 60(6):. PubMed ID: 35361630
[TBL] [Abstract][Full Text] [Related]
5. Small Cell Lung Cancer in the Course of Idiopathic Pulmonary Fibrosis-Case Report and Literature Review.
Grodkiewicz M; Koziel P; Chmielewska I; Korbel MA; Milanowski J
Curr Oncol; 2022 Jul; 29(7):5077-5083. PubMed ID: 35877261
[TBL] [Abstract][Full Text] [Related]
6. Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer.
Reck M; Horn L; Novello S; Barlesi F; Albert I; Juhász E; Kowalski D; Robinet G; Cadranel J; Bidoli P; Chung J; Fritsch A; Drews U; Wagner A; Govindan R
J Thorac Oncol; 2019 Apr; 14(4):701-711. PubMed ID: 30677506
[TBL] [Abstract][Full Text] [Related]
7. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study.
Yamamoto Y; Yano Y; Kuge T; Okabe F; Ishijima M; Uenami T; Kanazu M; Akazawa Y; Yamaguchi T; Mori M
Thorac Cancer; 2020 Nov; 11(11):3317-3325. PubMed ID: 32986306
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
Salgia R; Stille JR; Weaver RW; McCleod M; Hamid O; Polzer J; Roberson S; Flynt A; Spigel DR
Lung Cancer; 2017 Mar; 105():7-13. PubMed ID: 28236984
[TBL] [Abstract][Full Text] [Related]
10. The feasibility study of Carboplatin plus Etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias.
Minegishi Y; Kuribayashi H; Kitamura K; Mizutani H; Kosaihira S; Okano T; Seike M; Azuma A; Yoshimura A; Kudoh S; Gemma A
J Thorac Oncol; 2011 Apr; 6(4):801-7. PubMed ID: 21336181
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis.
Watanabe N; Taniguchi H; Kondoh Y; Kimura T; Kataoka K; Nishiyama O; Kondo M; Hasegawa Y
Int J Clin Oncol; 2014 Apr; 19(2):260-5. PubMed ID: 23592279
[TBL] [Abstract][Full Text] [Related]
12. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy in idiopathic pulmonary fibrosis and small-cell lung cancer with poor lung function.
Zhang X; Li W; Li C; Zhang J; Su Z
BMC Pulm Med; 2021 Apr; 21(1):122. PubMed ID: 33858421
[TBL] [Abstract][Full Text] [Related]
14. Idiopathic pulmonary fibrosis in small cell lung cancer as a predictive factor for poor clinical outcome and risk of its exacerbation.
Koyama N; Iwai Y; Nagai Y; Aoshiba K; Nakamura H
PLoS One; 2019; 14(8):e0221718. PubMed ID: 31442290
[TBL] [Abstract][Full Text] [Related]
15. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer.
Reck M; von Pawel J; Macha HN; Kaukel E; Deppermann KM; Bonnet R; Ulm K; Hessler S; Gatzemeier U
J Natl Cancer Inst; 2003 Aug; 95(15):1118-27. PubMed ID: 12902441
[TBL] [Abstract][Full Text] [Related]
17. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
Heigener DF; Manegold C; Jäger E; Saal JG; Zuna I; Gatzemeier U
Am J Clin Oncol; 2009 Feb; 32(1):61-4. PubMed ID: 19194127
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial.
Shimokawa T; Okamoto H; Machida R; Misumi Y; Hosomi Y; Yoneshima Y; Tanaka H; Okishio K; Simizu J; Goto K; Akamatsu H; Kubota K; Nakagawa K; Horinouchi H; Ando M; Kataoka T; Ohe Y
Lung Cancer; 2023 Jul; 181():107195. PubMed ID: 37156212
[TBL] [Abstract][Full Text] [Related]
19. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
[TBL] [Abstract][Full Text] [Related]
20. Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease.
Socinski MA; Kaye FJ; Spigel DR; Kudrik FJ; Ponce S; Ellis PM; Majem M; Lorigan P; Gandhi L; Gutierrez ME; Nepert D; Corral J; Ares LP
Clin Lung Cancer; 2017 Jan; 18(1):68-76.e2. PubMed ID: 28341109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
